Antitumor activity of Corynebacterium parvum.
D000276:Adjuvants, Immunologic; D000818:Animals; D000917:Antibody Formation; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001428:Bacterial Vaccines / Q000009:adverse effects / Q000627:therapeutic use; D006410:Hematopoiesis; D006801:Humans; D007111:Immunity, Cellular; D007167:Immunotherapy; D008264:Macrophages / Q000276:immunology; D012157:Mononuclear Phagocyte System / Q000276:immunology; D009374:Neoplasms, Experimental / Q000276:immunology / Q000517:prevention & control / Q000628:therapy*; D010587:Phagocytosis; D011425:Propionibacterium acnes / Q000276:immunology*
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D001428:Bacterial Vaccines